Passage Bio (PASG)
(Delayed Data from NSDQ)
$0.83 USD
0.00 (-0.31%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.83 0.00 (0.19%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
PASG 0.83 0.00(-0.31%)
Will PASG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PASG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PASG
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
PASG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Other News for PASG
Expanding Market and Promising Preclinical Results Bolster Buy Rating for Passage Bio
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Passage Bio received positive feedback in Type C meeting with FDA on PBFT02
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference